USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse